lorviqua
pfizer europe ma eeig - lorlatinib - karcinoma, nesīkšūnu plaušas - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.
orserdu
stemline therapeutics b.v. - elacestrant - krūts audzējs - endokrīnā terapija - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.
erlotinib sandoz 25 mg apvalkotās tabletes
sandoz d.d., slovenia - erlotinibs - apvalkotā tablete - 25 mg
erlotinib sandoz 100 mg apvalkotās tabletes
sandoz d.d., slovenia - erlotinibs - apvalkotā tablete - 100 mg
erlotinib sandoz 150 mg apvalkotās tabletes
sandoz d.d., slovenia - erlotinibs - apvalkotā tablete - 150 mg
erlotinib mylan 100 mg apvalkotās tabletes
mylan pharmaceuticals limited, ireland - erlotinibs - apvalkotā tablete - 100 mg
erlotinib mylan 150 mg apvalkotās tabletes
mylan pharmaceuticals limited, ireland - erlotinibs - apvalkotā tablete - 150 mg
erlotinib actavis 150 mg apvalkotās tabletes
actavis group ptc ehf., iceland - erlotinibs - apvalkotā tablete - 150 mg
erlotinib zentiva 25 mg apvalkotās tabletes
zentiva, k.s., czech republic - erlotinibs - apvalkotā tablete - 25 mg
erlotinib zentiva 100 mg apvalkotās tabletes
zentiva, k.s., czech republic - erlotinibs - apvalkotā tablete - 100 mg